Avera Pharmaceuticals, Inc. Completes Enrollment In Phase 2 Social Anxiety Disorder Study

SAN DIEGO--(BUSINESS WIRE)--Avera Pharmaceuticals, Inc. announced today it has completed enrollment in its ongoing Phase 2 study of the Neurokinin-1 (NK-1) antagonist AV608 in subjects with social anxiety disorder (also called social phobia).